miRNA drug for tendinopathy

治疗肌腱病的 miRNA 药物

基本信息

批准号：
10709649
负责人：
David T Fung
金额：
$ 56.9万
依托单位：
NEW YORK/R&D/CTR/TRANSLATIONAL MED/THER
依托单位国家：
美国
项目类别：
财政年份：
2022
资助国家：
美国
起止时间：
2022-09-30 至 2025-05-31
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10709649
关键词：
Adverse effects Affect Age Years Aging Animal Model Apoptosis Attention Binding Bioinformatics Biological Assay Businesses Chemicals Chronic Cicatrix Clinical Clinical Pathology Clinical Trials Data Databases Deterioration Disease Dose Drug Kinetics Equity Exhibits FDA approved Formulation Future Gene Expression Genes Histologic Human Hyaluronic Acid Impairment Individual Inflammation Inflammation Mediators Injections Investments Mediating Mediator Mesenchymal Stem Cells MicroRNAs Microarray Analysis Modeling Modification New York Non-Steroidal Anti-Inflammatory Agents Operative Surgical Procedures Oryctolagus cuniculus Outcome PKH 26 Pain Pathogenesis Pathology Pathway interactions Performance Pharmaceutical Preparations Phase Placebos Predisposing Factor Predisposition RNA Rattus Ribonucleotides Rodent Rodent Model Rupture Safety Schedule Site Steroids Swelling Technology Tendinopathy Tendon structure Testing Therapeutic Therapeutic Effect Tissues Toxic effect achilles tendon aging population biological adaptation to stress chronic inflammatory disease collagenase commercial application commercialization effective therapy efficacy evaluation efficacy testing exosome healing improved loss of function mechanical properties microRNA delivery novel novel therapeutic intervention novel therapeutics nuclease pain behavior phase 2 study pleiotropism repaired research and development response scaffold tendon rupture translational medicine translational therapeutics trend two-dimensional uptake

Adverse effects Affect Age Years Aging Animal Model Apoptosis Attention Binding Bioinformatics Biological Assay Businesses Chemicals Chronic Cicatrix Clinical Clinical Pathology Clinical Trials Data Databases Deterioration Disease Dose Drug Kinetics Equity Exhibits FDA approved Formulation Future Gene Expression Genes Histologic Human Hyaluronic Acid Impairment Individual Inflammation Inflammation Mediators Injections Investments Mediating Mediator Mesenchymal Stem Cells MicroRNAs Microarray Analysis Modeling Modification New York Non-Steroidal Anti-Inflammatory Agents Operative Surgical Procedures Oryctolagus cuniculus Outcome PKH 26 Pain Pathogenesis Pathology Pathway interactions Performance Pharmaceutical Preparations Phase Placebos Predisposing Factor Predisposition RNA Rattus Ribonucleotides Rodent Rodent Model Rupture Safety Schedule Site Steroids Swelling Technology Tendinopathy Tendon structure Testing Therapeutic Therapeutic Effect Tissues Toxic effect achilles tendon aging population biological adaptation to stress chronic inflammatory disease collagenase commercial application commercialization effective therapy efficacy evaluation efficacy testing exosome healing improved loss of function mechanical properties microRNA delivery novel novel therapeutic intervention novel therapeutics nuclease pain behavior phase 2 study pleiotropism repaired research and development response scaffold tendon rupture translational medicine translational therapeutics trend two-dimensional uptake

展开

项目摘要

Project Summary Tendinopathy is a tendon disorder that is highly prevalent in the aged population. It is characterized by tendon deterioration that often leads to tendon rupture, and is associated with pain, swelling and impaired performance. There is currently no cure for tendinopathy and an urgent need for effective treatments for tendinopathy. The technology to be developed is microRNA (miR)-221-5p for the treatment of tendinopathy. Our preliminary studies identified that miR-221-5p exhibited a therapeutic effect in a rodent model of tendinopathy and may exert its therapeutic effect, at least in part, by suppressing expression of pro-inflammatory mediators that contribute to the pathogenesis of tendinopathy. This project will test the hypothesis that chemically modified miR-221-5p exerts an enhanced effect on mitigating tendinopathy. The Phase II study will focus on providing critical evidence towards developing miR-221-5p as an FDA-approved product for the treatment of tendinopathy. In Aim 1, we will determine the chemical formulation and treatment condition of miR-221-5p using a collagenase- induced model of tendinopathy. In Aim 2, we will determine the efficacy and safety of miR-221-5p on tendinopathy in rabbits. Successful completion of the proposed studies will identify miR-221-5p as a new drug for the treatment of tendinopathy and other chronic inflammatory diseases.

项目摘要肌腱病是一种肌腱疾病，在老年人群中非常普遍。它的特征是肌腱恶化通常会导致肌腱破裂，并且与疼痛，肿胀和受损有关表现。目前尚无治愈肌腱病的治疗方法，迫切需要有效治疗肌腱病。要开发的技术是用于治疗肌腱病的microRNA（miR）-221-5p。我们的初步研究表明，miR-221-5p在肌腱病模型中表现出治疗作用并可能至少部分地通过抑制促炎性介体的表达来发挥其治疗作用这有助于肌腱病的发病机理。该项目将检验化学修改的假设 miR-221-5p对缓解肌腱病的影响增强。第二阶段研究将重点放在提供开发miR-221-5p作为FDA批准的产品的关键证据，用于治疗肌腱病。在AIM 1中，我们将使用胶原酶 - 诱导的肌腱病模型。在AIM 2中，我们将确定miR-221-5p的功效和安全性兔子中的肌腱病。成功完成拟议的研究将确定miR-221-5p为一种新药用于治疗肌腱病和其他慢性炎症性疾病。